199 related articles for article (PubMed ID: 24282289)
1. Anti-YKL-40 antibody and ionizing irradiation synergistically inhibit tumor vascularization and malignancy in glioblastoma.
Shao R; Francescone R; Ngernyuang N; Bentley B; Taylor SL; Moral L; Yan W
Carcinogenesis; 2014 Feb; 35(2):373-82. PubMed ID: 24282289
[TBL] [Abstract][Full Text] [Related]
2. Role of YKL-40 in the angiogenesis, radioresistance, and progression of glioblastoma.
Francescone RA; Scully S; Faibish M; Taylor SL; Oh D; Moral L; Yan W; Bentley B; Shao R
J Biol Chem; 2011 Apr; 286(17):15332-43. PubMed ID: 21385870
[TBL] [Abstract][Full Text] [Related]
3. Tumor-derived mural-like cells coordinate with endothelial cells: role of YKL-40 in mural cell-mediated angiogenesis.
Francescone R; Ngernyuang N; Yan W; Bentley B; Shao R
Oncogene; 2014 Apr; 33(16):2110-22. PubMed ID: 23665676
[TBL] [Abstract][Full Text] [Related]
4. A YKL-40-neutralizing antibody blocks tumor angiogenesis and progression: a potential therapeutic agent in cancers.
Faibish M; Francescone R; Bentley B; Yan W; Shao R
Mol Cancer Ther; 2011 May; 10(5):742-51. PubMed ID: 21357475
[TBL] [Abstract][Full Text] [Related]
5. Vascular heterogeneity and targeting: the role of YKL-40 in glioblastoma vascularization.
Shao R; Taylor SL; Oh DS; Schwartz LM
Oncotarget; 2015 Dec; 6(38):40507-18. PubMed ID: 26439689
[TBL] [Abstract][Full Text] [Related]
6. On-target JAK2/STAT3 inhibition slows disease progression in orthotopic xenografts of human glioblastoma brain tumor stem cells.
Stechishin OD; Luchman HA; Ruan Y; Blough MD; Nguyen SA; Kelly JJ; Cairncross JG; Weiss S
Neuro Oncol; 2013 Feb; 15(2):198-207. PubMed ID: 23262510
[TBL] [Abstract][Full Text] [Related]
7. CDH5 is specifically activated in glioblastoma stemlike cells and contributes to vasculogenic mimicry induced by hypoxia.
Mao XG; Xue XY; Wang L; Zhang X; Yan M; Tu YY; Lin W; Jiang XF; Ren HG; Zhang W; Song SJ
Neuro Oncol; 2013 Jul; 15(7):865-79. PubMed ID: 23645533
[TBL] [Abstract][Full Text] [Related]
8. EphA3 maintains tumorigenicity and is a therapeutic target in glioblastoma multiforme.
Day BW; Stringer BW; Al-Ejeh F; Ting MJ; Wilson J; Ensbey KS; Jamieson PR; Bruce ZC; Lim YC; Offenhäuser C; Charmsaz S; Cooper LT; Ellacott JK; Harding A; Leveque L; Inglis P; Allan S; Walker DG; Lackmann M; Osborne G; Khanna KK; Reynolds BA; Lickliter JD; Boyd AW
Cancer Cell; 2013 Feb; 23(2):238-48. PubMed ID: 23410976
[TBL] [Abstract][Full Text] [Related]
9. Treating brain tumor-initiating cells using a combination of myxoma virus and rapamycin.
Zemp FJ; Lun X; McKenzie BA; Zhou H; Maxwell L; Sun B; Kelly JJ; Stechishin O; Luchman A; Weiss S; Cairncross JG; Hamilton MG; Rabinovich BA; Rahman MM; Mohamed MR; Smallwood S; Senger DL; Bell J; McFadden G; Forsyth PA
Neuro Oncol; 2013 Jul; 15(7):904-20. PubMed ID: 23585629
[TBL] [Abstract][Full Text] [Related]
10. Ionizing radiations sustain glioblastoma cell dedifferentiation to a stem-like phenotype through survivin: possible involvement in radioresistance.
Dahan P; Martinez Gala J; Delmas C; Monferran S; Malric L; Zentkowski D; Lubrano V; Toulas C; Cohen-Jonathan Moyal E; Lemarie A
Cell Death Dis; 2014 Nov; 5(11):e1543. PubMed ID: 25429620
[TBL] [Abstract][Full Text] [Related]
11. N-cadherin upregulation mediates adaptive radioresistance in glioblastoma.
Osuka S; Zhu D; Zhang Z; Li C; Stackhouse CT; Sampetrean O; Olson JJ; Gillespie GY; Saya H; Willey CD; Van Meir EG
J Clin Invest; 2021 Mar; 131(6):. PubMed ID: 33720050
[TBL] [Abstract][Full Text] [Related]
12. CD133+ glioblastoma stem-like cells induce vascular mimicry in vivo.
Chiao MT; Yang YC; Cheng WY; Shen CC; Ko JL
Curr Neurovasc Res; 2011 Aug; 8(3):210-9. PubMed ID: 21675958
[TBL] [Abstract][Full Text] [Related]
13. Loss of endothelial programmed cell death 10 activates glioblastoma cells and promotes tumor growth.
Zhu Y; Zhao K; Prinz A; Keyvani K; Lambertz N; Kreitschmann-Andermahr I; Lei T; Sure U
Neuro Oncol; 2016 Apr; 18(4):538-48. PubMed ID: 26254477
[TBL] [Abstract][Full Text] [Related]
14. Celecoxib and radioresistant glioblastoma-derived CD133+ cells: improvement in radiotherapeutic effects. Laboratory investigation.
Ma HI; Chiou SH; Hueng DY; Tai LK; Huang PI; Kao CL; Chen YW; Sytwu HK
J Neurosurg; 2011 Mar; 114(3):651-62. PubMed ID: 21054139
[TBL] [Abstract][Full Text] [Related]
15. Tumor microenvironment tenascin-C promotes glioblastoma invasion and negatively regulates tumor proliferation.
Xia S; Lal B; Tung B; Wang S; Goodwin CR; Laterra J
Neuro Oncol; 2016 Apr; 18(4):507-17. PubMed ID: 26320116
[TBL] [Abstract][Full Text] [Related]
16. Arsenic trioxide sensitizes cancer stem cells to chemoradiotherapy. A new approach in the treatment of inoperable glioblastoma multiforme.
Tomuleasa C; Soritau O; Kacso G; Fischer-Fodor E; Cocis A; Ioani H; Timis T; Petrescu M; Cernea D; Virag P; Irimie A; Florian IS
J BUON; 2010; 15(4):758-62. PubMed ID: 21229642
[TBL] [Abstract][Full Text] [Related]
17. YKL-40 expression is associated with poorer response to radiation and shorter overall survival in glioblastoma.
Pelloski CE; Mahajan A; Maor M; Chang EL; Woo S; Gilbert M; Colman H; Yang H; Ledoux A; Blair H; Passe S; Jenkins RB; Aldape KD
Clin Cancer Res; 2005 May; 11(9):3326-34. PubMed ID: 15867231
[TBL] [Abstract][Full Text] [Related]
18. Blockade of TGF-β signaling by the TGFβR-I kinase inhibitor LY2109761 enhances radiation response and prolongs survival in glioblastoma.
Zhang M; Kleber S; Röhrich M; Timke C; Han N; Tuettenberg J; Martin-Villalba A; Debus J; Peschke P; Wirkner U; Lahn M; Huber PE
Cancer Res; 2011 Dec; 71(23):7155-67. PubMed ID: 22006998
[TBL] [Abstract][Full Text] [Related]
19. Antibody directed against human YKL-40 increases tumor volume in a human melanoma xenograft model in scid mice.
Salamon J; Hoffmann T; Elies E; Peldschus K; Johansen JS; Lüers G; Schumacher U; Wicklein D
PLoS One; 2014; 9(4):e95822. PubMed ID: 24752554
[TBL] [Abstract][Full Text] [Related]
20. TrkB-containing exosomes promote the transfer of glioblastoma aggressiveness to YKL-40-inactivated glioblastoma cells.
Pinet S; Bessette B; Vedrenne N; Lacroix A; Richard L; Jauberteau MO; Battu S; Lalloué F
Oncotarget; 2016 Aug; 7(31):50349-50364. PubMed ID: 27385098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
